HER2 Support Group Forums - View Single Post

Lolly · 08-02-2007, 03:05 PM

Here's a link to an article about AstraZeneca aquiring Kudos Pharmaceuticals and then a brief outline of the trial drug which I think is the one Leea is getting. The article was published in 2005 so it describes the trial as Phase I

Medical News Today
http://www.medicalnewstoday.com/articles/35420.php

"...The acquisition of KuDOS Pharmaceuticals augments AstraZeneca's portfolio with clinical and pre-clinical compounds and programmes. An innovative, targeted compound, KU 59436, an oral poly-ADP-ribose polymerase (PARP) enzyme inhibitor, is currently in phase I clinical development.

PARP is a key signalling enzyme involved in triggering repair of single strand DNA damage. PARP inhibition selectively kills tumour cells lacking the homologous recombination (HR) DNA repair pathway whilst sparing normal cells. Known defects in HR repair include the well-characterised hereditary BRCA1 and BRCA2 mutations in breast and ovarian cancer for which diagnostic tests are available. This therapeutic/diagnostic combination offers the exciting potential that KU 59436 can be developed as a new cancer monotherapy targeted for the benefit of a definable patient population..."

08-02-2007, 03:05 PM	#8
Lolly Senior Member Join Date: Aug 2001 Location: Oregon Posts: 1,756	Here's a link to an article about AstraZeneca aquiring Kudos Pharmaceuticals and then a brief outline of the trial drug which I think is the one Leea is getting. The article was published in 2005 so it describes the trial as Phase I Medical News Today http://www.medicalnewstoday.com/articles/35420.php "...The acquisition of KuDOS Pharmaceuticals augments AstraZeneca's portfolio with clinical and pre-clinical compounds and programmes. An innovative, targeted compound, KU 59436, an oral poly-ADP-ribose polymerase (PARP) enzyme inhibitor, is currently in phase I clinical development. PARP is a key signalling enzyme involved in triggering repair of single strand DNA damage. PARP inhibition selectively kills tumour cells lacking the homologous recombination (HR) DNA repair pathway whilst sparing normal cells. Known defects in HR repair include the well-characterised hereditary BRCA1 and BRCA2 mutations in breast and ovarian cancer for which diagnostic tests are available. This therapeutic/diagnostic combination offers the exciting potential that KU 59436 can be developed as a new cancer monotherapy targeted for the benefit of a definable patient population..." __________________ Sept.'99 - Dx.Stage IIIB, IDC ER/PR-, HER2+++ by IHC, confirmed '04 by FISH. Left MRM, AC x's 4, Taxol x's 4, 33 Rads, finishing Tx May 2000. Jan.'01 - local/regional recurrence, Stage IV. Herceptin/Navelbine weekly till NED August 2001, then maintenance Herceptin. Right Mast. April 2002. Local/Regional recurrence April '04, Herceptin plus/minus chemo until May '07. Gemzar added from Feb.'07-April '07; Tykerb/Abraxane until August '07, back on Herceptin plus Taxotere and Xeloda Sept. '07. Stopped T/X Nov. '07, stopped Herceptin Dec. '07, started Avastin/Taxol/Carboplatin Dec. '07. Progression in chest skin, stopped TAC March '03, started radiation. Herceptin has served as the "Backbone" of my treatment strategy for over 6 years, giving me great quality of life. In 2005, I was privileged to participate in the University of Washington/Seattle HER2 Vaccine Trial.